IMNP - Immune Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue--2
Cost of Revenue---
Gross Profit--2
Operating Expenses
Research Development8,3335,9355,640
Selling General and Administrative6,4279,78910,725
Non Recurring12,50012,50012,500
Total Operating Expenses---
Operating Income or Loss-27,260-15,724-16,363
Income from Continuing Operations
Total Other Income/Expenses Net-8,702-606-3,783
Earnings Before Interest and Taxes-35,962-16,330-20,146
Interest Expense1,5558273,404
Income Before Tax-37,517-17,157-23,550
Income Tax Expense-4,856--
Minority Interest---
Net Income From Continuing Ops-32,661-17,157-23,550
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-32,661-17,157-23,550
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-40,634-24,116-24,422